JNJ-4703 / J&J - LARVOL DELTA

Pharmacodynamic Activity of JNJ-67484703 in Rheumatoid Arthritis, Ulcerative Colitis and Sjogren's disease (PARIS): Results of a Phase II Proof of Biology Trial (EULAR 2025) - "In RA, but not SjD or UC, 3 mg/kg JNJ-67484703 was associated with a reduction in PD1 hi Tfh/Tph in target tissue and other parameters of tissue inflammation, demonstrating the value of early proof of biology studies. Overall, JNJ-67484703 appeared safe and well-tolerated."

P2 data • PK/PD data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Sjogren's Syndrome • Ulcerative Colitis • CD4 • CXCL13 • IFNG

Safety, Tolerability, and Activity of JNJ-67484703 in Participants with Active Rheumatoid Arthritis: Results of a Multicenter, Double-blind, Placebo-controlled, Randomized, Multiple-dose Phase 1b Study (EULAR 2025) - "Stable doses of non-steroidal anti-inflammatory drugs and oral glucocorticoids < 10 mg prednisone equivalent were also permitted...All patients were receiving methotrexate, 72.7% were receiving oral glucocorticoids, and 40.9% were receiving NSAIDs... Overall, administration of JNJ-67484703 at 2 mg/kg and 3 mg/kg through 10 weeks was safe and well-tolerated. Numerically greater improvement in Week 12 DAS28-CRP from baseline was observed in the 3 mg/kg group compared to placebo. Participants treated with JNJ-67484703 showed a selective decrease in circulating PD-1 + T cells."

Clinical • IO biomarker • P1 data • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Nephrology • Oncology • Pneumonia • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • CD4 • CD8 • CRP

Efficacy, Safety, and Tolerability of JNJ-67484703 in Adult Patients With Moderate to Severe Atopic Dermatitis: Design of a Phase 2a Study (EADV 2023) - P2 | "The RESTORE-AD phase 2 study will evaluate the efficacy, safety, and tolerability of JNJ-67484703 in adults with moderate and severe AD, using multiple clinical outcome measures."

Clinical • P2a data • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Immunology • Sleep Disorder

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=44 | Completed | Sponsor: Janssen Research & Development, LLC | Active, not recruiting ➔ Completed

Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=47 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: Nov 2022 ➔ May 2023

Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Study of JNJ-67484703 in the Treatment of Participants with Moderate to Severe Atopic Dermatitis (clinicaltrialsregister.eu) - P2 | N=51 | Ongoing | Sponsor: Janssen-Cilag International NV

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • Rheumatology

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - P1; N=42; Recruiting; Sponsor: Janssen Research & Development, LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Janssen Research & Development, LLC; Trial completion date: Sep 2023 ➔ Apr 2023

Clinical • Trial completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Janssen Research & Development, LLC; Trial completion date: Apr 2023 ➔ Sep 2023

Clinical • Trial completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - P1; N=42; Not yet recruiting; Sponsor: Janssen Research & Development, LLC

New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP